CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab. Authors here show that the change in levels of the chemokine CXCL13 shortly fo...
Na minha lista:
| Principais autores: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Portfolio
2022-11-01
|
| coleção: | Nature Communications |
| Acesso em linha: | https://doi.org/10.1038/s41467-022-34873-7 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|